Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Miconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Galt Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Galt Pharmaceuticals® Acquires Oravig® (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics
Details : Oravig is the first and only muco-adhesive buccal tablet formulation of miconazole approved to treat oropharyngeal candidiasis (OPC), also known as oral thrush, in adult patients in the United States.
Brand Name : Oravig
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 16, 2020
Lead Product(s) : Miconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Galt Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?